143 related articles for article (PubMed ID: 12682407)
41. Important classes of bioactive alkaloids from marine ascidians: structures, isolation and bioactivity.
Menna M
Curr Top Med Chem; 2014; 14(2):207-23. PubMed ID: 24359200
[TBL] [Abstract][Full Text] [Related]
42. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573
[TBL] [Abstract][Full Text] [Related]
43. Unique features of the mode of action of ET-743.
D'Incalci M; Erba E; Damia G; Galliera E; Carrassa L; Marchini S; Mantovani R; Tognon G; Fruscio R; Jimeno J; Faircloth GT
Oncologist; 2002; 7(3):210-6. PubMed ID: 12065793
[TBL] [Abstract][Full Text] [Related]
44. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Guirouilh-Barbat J; Antony S; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):2007-14. PubMed ID: 19584237
[TBL] [Abstract][Full Text] [Related]
45. Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata.
Guan Y; Sakai R; Rinehart KL; Wang AH
J Biomol Struct Dyn; 1993 Apr; 10(5):793-818. PubMed ID: 8318161
[TBL] [Abstract][Full Text] [Related]
46. Structure elucidation and 1H/13C NMR spectral assignments of four trabectedin related compounds.
Vermeulen W; Filliers W; García C; Manzanaro S; Montalvo D; Polanco C; Spillemaeckers F; Van Hoof B; Winderickx G; Somers I; Rodriguez-Campos I
Magn Reson Chem; 2008 Dec; 46(12):1198-202. PubMed ID: 18821578
[TBL] [Abstract][Full Text] [Related]
47. ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem.
Manning T; Rhodes E; Loftis R; Phillips D; Demaria D; Newman D; Rudloe J
Nat Prod Res; 2006 May; 20(5):461-73. PubMed ID: 16644544
[TBL] [Abstract][Full Text] [Related]
48. Tyrosinium-D-tetrahydroisoquinoline-3-carboxylate 1.5-hydrate and tyrosyl-D-tetrahydroisoquinoline-3-carboxamide hydrate.
Deschamps JR; Flippen-Anderson JL; Moore C; Cudney R; George C
Acta Crystallogr C; 1997 Oct; 53 ( Pt 10)():1478-82. PubMed ID: 9362554
[TBL] [Abstract][Full Text] [Related]
49. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Sparidans RW; Rosing H; Hillebrand MJ; López-Lázaro L; Jimeno JM; Manzanares I; van Kesteren C; Cvitkovic E; van Oosterom AT; Schellens JH; Beijnen JH
Anticancer Drugs; 2001 Sep; 12(8):653-66. PubMed ID: 11604552
[TBL] [Abstract][Full Text] [Related]
50. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
51. Some hope from marine natural products.
D'Incalci M
Ann Oncol; 1998 Sep; 9(9):937-8. PubMed ID: 9818065
[No Abstract] [Full Text] [Related]
52. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
53. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents.
Martinez EJ; Corey EJ
Org Lett; 2000 Apr; 2(7):993-6. PubMed ID: 10768205
[TBL] [Abstract][Full Text] [Related]
54. Transcription of the multidrug resistance gene MDR1: a therapeutic target.
Scotto KW; Johnson RA
Mol Interv; 2001 Jun; 1(2):117-25. PubMed ID: 14993331
[TBL] [Abstract][Full Text] [Related]
55. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
56. DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands.
Marco E; Gago F
Mol Pharmacol; 2005 Dec; 68(6):1559-67. PubMed ID: 16150929
[TBL] [Abstract][Full Text] [Related]
57. Marine natural products as anticancer drugs.
Simmons TL; Andrianasolo E; McPhail K; Flatt P; Gerwick WH
Mol Cancer Ther; 2005 Feb; 4(2):333-42. PubMed ID: 15713904
[TBL] [Abstract][Full Text] [Related]
58. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
van Kesteren C; Mathĵt RA; López-Lázaro L; Cvitkovic E; Taamma A; Jimeno JM; Guzman C; Schellens JH; Misset JL; Brain E; Hillebrand MJ; Rosing H; Beijnen JH
Cancer Chemother Pharmacol; 2001 Dec; 48(6):459-66. PubMed ID: 11800026
[TBL] [Abstract][Full Text] [Related]
59. Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743.
Rath CM; Janto B; Earl J; Ahmed A; Hu FZ; Hiller L; Dahlgren M; Kreft R; Yu F; Wolff JJ; Kweon HK; Christiansen MA; Håkansson K; Williams RM; Ehrlich GD; Sherman DH
ACS Chem Biol; 2011 Nov; 6(11):1244-56. PubMed ID: 21875091
[TBL] [Abstract][Full Text] [Related]
60. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
